Skip to main content
News > News > Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults

Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults

Authors: Kimberly P Kicielinski, E Antonio Chiocca, John S Yu, George M Gill,Matt Coffey and James M Markert

Date: Feb. 20, 2014

Full Article: http://www.nature.com/mt/journal/v22/n5/full/mt201421a.html

Reovirus, an oncolytic RNA virus exhibiting antiglioma activity, was shown in a previous single institution phase 1 study found that the inoculation of the virus to be well tolerated in patients with recurrent malignant glioma (MG).

We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is advancing research that ordinarily has not generated a public value or been recognized. This approach particularly helps underserved scientists to collaborate with their more financially capable colleagues.

How open science helps researchers succeed:

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers.

The review of the literature demonstrates that open science is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open science practices bring significant benefits to researchers relative to more traditional closed practices.

Secured By miniOrange